(A) Co-IP assays showing the co-IP of endogenous hUpf1 and PABPC1 and HuR proteins with an antibody against eRF3 (α-eRF3; 1%, 3%, 10%, 30%, and 100% of pellet loaded in lanes 4–8, respectively), or pre-immune serum (Pre-I, lane 1) as a control. 3% and 0.6% of the total lysate are shown in lanes 2 and 3, respectively.
(B) In vitro pull-down assays showing anti-FLAG Western blots of pull-down pellets (upper panels) resulting after myc-tagged eRF3 (lanes 4–7) or no myc-tagged protein (lanes 1–3), immobilized on an anti-myc antibody resin, was incubated with various amounts of FLAG-tagged hUpf1, PABPC1, or hnRNP A1 as indicated. Estimated amounts of FLAG-tagged proteins in each reaction are given in μM. Bottom panels show 5% of input protein for each reaction. The asterisk (*) and dagger (†) on the right indicates likely degradation products of PABPC1 and cross-reacting Myc-eRF3, respectively.
(C) Lanes 1–6: Western blot for exogenously expressed Myc-tagged eRF3 (wt, lanes 1–3) or eRF3 KAKA mutant protein (KAKA, lanes 4–6) that co-IP with FLAG-tagged PABPC1, hUpf1, or as a negative control, MS2, as indicated above the lanes. Lanes 7–9: Western blot for exogenously expressed Myc-tagged eRF1 that co-IP with FLAG-tagged eRF3, eRF3 KAKA mutant protein, or as a negative control, MS2, as indicated above the lanes. For all lanes, 5% of total input extracts are shown in the bottom panels.